Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.

Fiona Thoi1, Daniel J Scherer2, David M Kaye3

  • 1School of Medicine, University of Adelaide, Adelaide, SA, Australia.

Heart, Lung & Circulation
|February 14, 2022
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suppression of Post-Ischemic Cardiac Remodelling and Inflammatory Response by a Novel Sphingolipid Modifier, CIN038.

International journal of molecular sciences·2026
Same author

An abbreviated exercise right heart catheterization protocol for the diagnosis of heart failure with preserved ejection fraction.

Journal of cardiac failure·2026
Same author

Aortic Stenosis and Heart Failure With Preserved Ejection Fraction: A Cautionary Tale of Common Partners.

Circulation. Heart failure·2026
Same author

Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II.

JACC. Heart failure·2026
Same author

Using biofilm-targeting local antibiotics to treat recalcitrant medical device-associated infections: driveline infection as a model.

The Journal of antimicrobial chemotherapy·2026
Same author

Beta-blocker therapy after myocardial infarction: an umbrella review.

EClinicalMedicine·2026

Methamphetamine-associated cardiomyopathy (MA-CMP) is a growing cause of heart failure, particularly in younger individuals. Early recognition and abstinence are crucial for managing this severe condition.

Area of Science:

  • Cardiology
  • Toxicology
  • Public Health

Background:

  • Global methamphetamine use is rising, creating significant health and societal issues.
  • Methamphetamine-associated cardiomyopathy (MA-CMP) is an emerging cause of heart failure.
  • MA-CMP contributes substantially to hospital admissions and chronic heart failure care.

Purpose of the Study:

  • To highlight the increasing burden of MA-CMP.
  • To discuss the unique challenges in recognizing, managing, and treating MA-CMP.
  • To emphasize the need for clinician awareness of MA-CMP.

Main Methods:

  • This study is a review of current literature and clinical observations regarding MA-CMP.
  • It synthesizes information on the prevalence, presentation, and management of MA-CMP.
Keywords:
AmphetamineDilated cardiomyopathyHeart failureMethamphetamine

Related Experiment Videos

  • The focus is on the clinical challenges posed by methamphetamine addiction and heart failure.

    • Main Results:

    • MA-CMP presents unique diagnostic challenges, especially in young patients with new heart failure.
    • The condition is often severe at presentation and associated with significant complications.
    • Abstinence from methamphetamine is fundamental to management.

    Conclusions:

    • MA-CMP represents a significant and increasing cause of heart failure.
    • Effective management requires addressing methamphetamine addiction and understanding specific clinical challenges.
    • Clinicians managing heart failure must be aware of MA-CMP, particularly in regions with high methamphetamine use like Australia.